A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.

Ratner ES;Keane FK;Lindner R;TASSI, Renata Alessandra;Paranjape T;Glasgow M;Nallur S;Deng Y;Lu L;Steele L;Sand S;Muller RU;BIGNOTTI, Eliana;BELLONE, Stefania;Boeke M;Yao X;PECORELLI, Sergio;RAVAGGI, Antonella;Katsaros D;Zelterman D;Cristea MC;Yu H;Rutherford TJ;Weitzel JN;Neuhausen SL;Schwartz PE;Slack FJ;Santin AD;Weidhaas J.B.

2011-01-01